Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc (formerly listed on Nasdaq under the symbol VRNA) generated a steady stream of news as a biopharmaceutical company focused on chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). Its news flow has covered the clinical development, regulatory progress and commercialization of its first-in-class COPD maintenance therapy Ohtuvayre (ensifentrine), as well as major corporate events culminating in its acquisition by Merck.
News articles about Verona Pharma include updates on the Phase 3 ENHANCE program for Ohtuvayre, where the drug met primary endpoints in ENHANCE-1 and ENHANCE-2 with statistically significant and clinically meaningful improvements in lung function. The company has also announced multiple scientific presentations at leading respiratory conferences such as the European Respiratory Society (ERS) International Congress and the American Thoracic Society (ATS) Conference, highlighting subgroup analyses on exacerbation rates, dyspnea, quality of life and outcomes in patients with comorbid conditions like cardiac disorders and type 2 diabetes.
Investors following VRNA-related news will also find corporate and financial updates, including quarterly financial results that detail Ohtuvayre net sales, prescription trends, prescriber adoption, and Verona’s funding and debt arrangements. Additional releases have described regulatory milestones, such as approval of Ohtuvayre in Macau through a development partner in Greater China and ongoing regulatory activities for potential marketing applications in other regions.
A key component of Verona Pharma’s news history is its strategic transaction with Merck. Press releases and SEC-related communications outline the July 2025 definitive agreement for Merck to acquire Verona Pharma, subsequent shareholder approval, court sanction of the scheme of arrangement, and Merck’s October 2025 announcement that the acquisition had closed and Verona Pharma had become a wholly owned subsidiary. Coverage of this process includes details of the cash consideration per ordinary share and per ADS and the resulting delisting of VRNA from the Nasdaq Global Market.
This news page serves as an archive of Verona Pharma’s historical announcements, from clinical and commercial milestones for Ohtuvayre to the corporate steps leading to its integration into Merck. Readers interested in the evolution of VRNA, the development of ensifentrine-based therapies, and the transaction that removed Verona Pharma from public markets can use this feed to review the company’s key public communications over time.
Summary not available.
Summary not available.
Summary not available.
Verona Pharma (Nasdaq: VRNA), a clinical-stage biopharmaceutical company, will announce its financial results for the first quarter ended March 31, 2023, on May 9, 2023. The company will host a conference call at 9:00 a.m. EDT to discuss the results and provide a corporate update. Participants can join the call by dialing +1-833-816-1396 for US callers or +1-412-317-0489 for international callers. A live webcast will also be available on their Investors page. Verona Pharma is focused on developing innovative therapies for chronic respiratory diseases. Their product candidate, ensifentrine, aims to combine bronchodilator and anti-inflammatory activities and has shown positive results in Phase 3 trials.
Verona Pharma plc (Nasdaq: VRNA) has announced that its development partner, Nuance Pharma, has begun dosing participants in the ENHANCE - China Phase 3 trial for ensifentrine, aimed at treating chronic obstructive pulmonary disease (COPD). This milestone follows the clearance of an Investigational New Drug application by the Center of Drug Evaluation in August 2022. Ensifentrine has shown promising results in prior Phase 3 trials, demonstrating significant improvements in lung function and reduced COPD exacerbations. Up to $179 million in milestone payments plus royalties are anticipated from Nuance Pharma's commercialization efforts in Greater China. An NDA for ensifentrine is expected to be submitted to the FDA in Q2 2023, reflecting Verona's commitment to addressing unmet needs in respiratory disease treatment.
Nuance Pharma has initiated dosing for the first patient in the ENHANCE - China Phase III Trial, focusing on the maintenance treatment of chronic obstructive pulmonary disease (COPD) using Ensifentrine. This innovative drug is a first-in-class dual inhibitor of phosphodiesterase enzymes, which combines bronchodilation and anti-inflammatory effects. The trial represents a significant advancement in Nuance Pharma's collaboration with Verona Pharma, which recently reported positive outcomes from previous Phase III trials. Ensifentrine aims to deliver substantial improvements in lung function and quality of life for COPD patients. Verona Pharma plans to submit a New Drug Application to the FDA in Q2 2023 for Ensifentrine following these promising results.
The acute respiratory distress syndrome (ARDS) pipeline is experiencing substantial growth, with over 100 active players working on 105 pipeline therapies. The increase in ARDS incidence is driving research and development in this sector, making it a lucrative market for new treatments. Companies like Biocon, NRx Pharmaceuticals, and Veru Healthcare are at the forefront of this effort, focusing on innovative therapies such as Itolizumab and Lenzilumab. Notably, Tetra Bio-Pharma secured $150,000 in funding for its ARDS-003 oral formulation development. The report highlights diverse therapeutic approaches, including cell replacements and targeted pharmacological agents.
The Annual General Meeting (AGM) of Swedish Orphan Biovitrum AB (Sobi) is scheduled for May 9, 2023, at 15:00 in Stockholm. Shareholders can vote in person or by postal voting, with deadlines for participation set on April 28 and May 3, 2023. The agenda includes the presentation of the annual report, election of board members, and approval of incentive programs aimed at aligning employee interests with shareholders. Notably, no dividend is proposed, and the board suggests SEK 1,725,000 for the chairman's fee and SEK 570,000 for other board members. The implementation of management and employee share incentive programs is also on the agenda.
The COPD and asthma devices market was valued at US$ 43.4 Billion in 2022 and is projected to reach US$ 60.4 Billion by 2028, with a CAGR of 5.66%.
This growth is driven by factors like the increasing elderly population prone to respiratory disorders, rising instances of diseases due to smoking, and enhanced healthcare spending.
Moreover, innovations in medical solutions, such as portable drug delivery devices, are expected to further propel market development. The report segments the market by product type, indication, distribution channel, and region, highlighting North America, Asia-Pacific, and Europe as key areas.
Verona Pharma plc (Nasdaq: VRNA) reported significant progress in its Phase 3 ENHANCE trials for ensifentrine, aimed at treating chronic obstructive pulmonary disease (COPD), indicating a potential shift in treatment paradigms. The company plans to submit a New Drug Application to the FDA in Q2 2023 and anticipates a US commercial launch in 2024, contingent on approval. Financially, Verona strengthened its position with a $150 million equity offering and a $150 million debt facility, extending its cash runway through at least 2025. For Q4 2022, R&D expenses decreased to $6.8 million, and the net loss narrowed to $10.5 million, reflecting improved operational efficiency.